Danaher, FDA autorizza test Cepheid per febbri emorragiche
- Il 3 novembre 2026, la FDA autorizza Xpert Hemorrhagic Fever Panel di Cepheid, controllata di Danaher.
- Il test rileva Ebola e altri virus responsabili di febbri emorragiche da un singolo campione, con risultati in circa 61 minuti.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Danaher Corporation published the original content used to generate this news brief via PR Newswire on November 03, 2026, and is solely responsible for the information contained therein.